Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01063829 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients
A Phase 2 study, sponsored by AiCuris Anti-infective Cures.
- Completed
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
NCT01063829 is a Phase 2 study that has completed, run by AiCuris Anti-infective Cures. The registered enrollment target is 133 participants.
The verdict
NCT01063829, a Phase 2 study, has completed, sponsored by AiCuris Anti-infective Cures.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
Study Summary
The aim of the study is to find out whether AIC246 is safe and efficacious in lowering the chances of the cytomegalovirus becoming active again and causing illness after an HBPC transplant (allogeneic stem cell transplant).
Interventions
- OTHER Placebo
- DRUG 60 mg AIC246
- DRUG 120 mg AIC246
- DRUG 240 mg AIC246
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01063829
The ClinicalTrials.gov registry entry for NCT01063829 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AiCuris Anti-infective Cures, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01063829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01063829 about?
NCT01063829 is a clinical study titled "Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients". The aim of the study is to find out whether AIC246 is safe and efficacious in lowering the chances of the cytomegalovirus becoming active again and causing illness after an HBPC transplant (allogeneic stem cell transplant).
What is the current status of trial NCT01063829?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2010-03. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01063829?
The interventions under investigation include: Placebo (OTHER), 60 mg AIC246 (DRUG), 120 mg AIC246 (DRUG), 240 mg AIC246 (DRUG).
Who is sponsoring clinical trial NCT01063829?
This trial is sponsored by AiCuris Anti-infective Cures, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.